IGALMI (BXCL501)
Acute agitation associated with schizophrenia or bipolar I or II disorder
ApprovedCommercial
Key Facts
Indication
Acute agitation associated with schizophrenia or bipolar I or II disorder
Phase
Approved
Status
Commercial
Company
About BioXcel Therapeutics
BioXcel Therapeutics utilizes its proprietary AI platform to identify and develop new therapeutic applications for existing drugs, focusing on high-need neuropsychiatric and immuno-oncology indications. The company achieved its first commercial approval with IGALMI and is actively expanding its pipeline, including promising Phase 2 results for BXCL501 in opioid withdrawal. Despite commercial challenges, BioXcel continues to pursue strategic financing and clinical development to address significant unmet medical needs.
View full company profile